Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Roivant Sciences (NASDAQ:ROIV) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The table below provides a concise overview o
Cantor Fitzgerald Reiterates Overweight on Roivant Sciences
Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.
Roivant Sciences' (NASDAQ:ROIV) Performance Raises Some Questions
Even though Roivant Sciences Ltd. (NASDAQ:ROIV) posted strong earnings recently, the stock hasn't reacted in a large way. We decided to have a deeper look, and we believe that investors might be worr
Buy Rating Justified by Roivant Sciences' Growth Prospects and Strategic Pipeline Expansion
Piper Sandler Keeps Their Buy Rating on Roivant Sciences (ROIV)
HC Wainwright & Co. : The Roivant Sciences (ROIV.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $18.00 to $18.00.
HC Wainwright & Co. : The Roivant Sciences (ROIV.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $18.00 to $18.00.
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price target.
Roivant Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 71.43% HC Wainwright & Co. $18 → $18 Reiterates Buy → Buy 04/22/2024 71.43% HC Wainwright & Co.
Roivant Sciences Ltd: Guggenheim increases price target from $16 to $18
Roivant Sciences Ltd: Guggenheim increases price target from $16 to $18
Express News | Roivant Sciences Ltd : Guggenheim Raises Target Price to $18 From $16
Analysts Conflicted on These Healthcare Names: Canopy Growth (CGC), Ultragenyx Pharmaceutical (RARE) and Roivant Sciences (ROIV)
Risinger Recommends 'Buy' for Roivant Sciences With Optimistic Brepocitinib Revenue Forecast and Increased Price Target
10-K: Annual report
Daily short sale tracking: American Airlines's short volume increased by 22 million, with a short sale ratio of 17%
American Airlines(AAL.US) ranked top of the list had the largest change in short volume (22.1 million shares), and the short volume ratio of Levi Strauss & Co.(LEVI.US) reached 48.04%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Express News | Roivant Sciences Ltd: Novaquest Agreement Amendment Provides for Elimination of Fixed Quarterly Payments Totaling $176.3 Mln
Express News | Roivant Sciences Ltd: On May 24, 2024, Dermavant Entered Into an Amendment to Novaquest Agreement
Roivant Sciences' Fiscal Q4 Net Loss Widens, Revenue Rises
Roivant Sciences (ROIV) reported a fiscal Q4 net loss Thursday of $0.19 per diluted share, widening from a loss of $0.05 a year earlier. Analysts polled by Capital IQ expected a loss of $0.30. Net rev
Express News | Roivant Sciences Ltd - in May 2024, Roivant Renegotiated Dermavant's Debt Obligations, Reducing Potential Cash Payments Due by Over $300M in Aggregate
Express News | Roivant Sciences Ltd - Consolidated Cash, Cash Equivalents and Restricted Cash of $6.6B at March 31, 2024, Supporting Cash Runway Into Profitability
Roivant Sciences 4Q Rev $28.9M >ROIV
Roivant Sciences 4Q Rev $28.9M >ROIV